Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor tyrosine-protein kinase erbB-2 (HER2) extracellular domain II (ECD II) is a critical structural region of the HER2 receptor, a member of the epidermal growth factor receptor (EGFR/ErbB) family of receptor tyrosine kinases. Unlike other members of the ErbB family, HER2 has no known ligand and exists in an active, 'open' conformation, making it the preferred heterodimerization partner for other ligand-activated ErbB receptors (such as EGFR, HER3, and HER4). Extracellular domain II contains the dimerization loop (or dimerization arm) that is essential for mediating these ligand-induced heterodimerization events. Heterodimerization, particularly the highly mitogenic HER2:HER3 complex, triggers the activation of intracellular tyrosine kinase domains, initiating downstream signaling cascades like the PI3K/Akt/mTOR and MAPK/ERK pathways that drive cell proliferation, survival, and migration. In many cancers, particularly breast, gastric, and gastroesophageal junction adenocarcinomas, HER2 is overexpressed or gene-amplified, leading to uncontrolled signaling and aggressive tumor growth. Additionally, oncogenic missense mutations within domain II (such as S310F and S310Y) can promote ligand-independent receptor activation. Therapeutic targeting of HER2 ECD II, primarily by the monoclonal antibody pertuzumab, sterically blocks the dimerization pocket, preventing heterodimerization and downstream signaling while also recruiting immune effector cells to induce antibody-dependent cell-mediated cytotoxicity (ADCC). Biparatopic agents like the bispecific antibody zanidatamab simultaneously target ECD II and ECD IV, leading to enhanced receptor clustering, internalization, and degradation, offering a powerful strategy to overcome resistance to traditional HER2-targeted therapies.
Inhibition of receptor heterodimerization (specifically blocking the dimerization loop of HER2 to prevent interaction with other ErbB family members like EGFR, HER3, and HER4), suppression of downstream PI3K/Akt and MAPK/ERK signaling pathways, induction of antibody-dependent cell-mediated cytotoxicity (ADCC), and promotion of receptor internalization and degradation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor tyrosine-protein kinase erbB-2 extracellular domain II (HER2 ECD II).